Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BNT162b2 in healthy Japanese adults
jRCT2071200045Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing BNT162b2 with Placebo (2 arms). Primary endpoints: Local reactions after dose 1 and dose 2, Systemic events after dose 1 and dose 2 and 8 more. Started Oct 2020; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200045.